FEG 2022 Dallas Investment Symposium

FEG 2022 DALLAS
INVESTMENT SYMPOSIUM

May 3, 2022 | Dallas, Texas

We are pleased to announce our first in-person event since 2019! The FEG 2022 Dallas Investment Symposium will be held at the Pegasus Park Campus on May 3, 2022 in Dallas, Texas. The day will feature four keynote sessions from industry leaders on investment and economic trends. Guests will have ample opportunity to connect with peers and learn about the Pegasus Park campus, which fosters innovation with biotech wet labs and co-working space. Find out more below!

The information on the webpage is for reference only. Contact us with any questions.

AGENDA

Tuesday, May 3, 2022

Pegasus Park
9:30 a.m.–11:00 a.m. Symposium Check-In
11:00 a.m.-11:10 a.m. FEG Welcome
11:10 a.m.–12:00 p.m.

Washington Policy Landscape and Political Outlook

Libby Cantrill, PIMCO

12:00 p.m.–1:00 p.m. Networking Lunch
1:00 p.m.–1:15 p.m.

Pegasus Park Intro

Tom Luce, Biotech Initiatives of Lyda Hill Philanthropies

1:15 p.m.-2:05 p.m.

Biotech Panel: Learning to Fly
with Eli Casdin and Kush Parmar, MD, Ph.D.

2:05 p.m.–2:50 p.m.

The Great Energy Debate

with John Baschab and Rod Saddington

2:50 p.m.–3:15 p.m. Afternoon Coffee Break
3:15 p.m.–4:05 p.m.

Bio Innovation through a New Lens
with Ben Lamm and Claire Aldridge, Ph.D.

4:05 p.m.–4:15 p.m. FEG Closing
4:15 p.m.–6:00 p.m. Networking and Cocktails

The dress code is business casual. Conference agenda items and times are subject to change.

KEYNOTE SPEAKERS

We are excited to welcome the following confirmed speakers:
Claire Aldridge, Ph.D.
Senior Vice President, Chief of Staff and Corporate Strategy | Taysha Gene Therapies

Claire will be participating in the fireside chat with Ben Lamm on Bio Innovation through a New Lens. Dr. Aldridge brings more than 20 years’ experience in roles that have included technology commercialization; improving patient outcomes through quality based initiatives; working with disease-specific nonprofits; development and venture philanthropy; and biotech and life science investing through venture capital.

Claire Aldridge, Ph.D.

Claire Aldridge, Ph.D. serves as Senior Vice President, Chief of Staff and Corporate Strategy at Taysha Gene Therapies, a Dallas based company focusing on eradicating monogenic CNS disease.  She previously served as Associate Vice President for Commercialization and Business Development at UT Southwestern Medical Center and VP, Venture Development with Remeditex Ventures, a local biotech venture fund. Dr. Aldridge brings more than 20 years’ experience facilitating the translation of scientific discoveries into patient and commercial benefits.

 

Dr. Aldridge has leveraged her training as a translator, or liaison, between scientists and non- scientists, communicating effectively about the potential of science. Her roles have included technology commercialization; improving patient outcomes through quality based initiatives; working with disease-specific nonprofits; development and venture philanthropy; and biotech and life science investing through venture capital.

 

Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.

John Baschab
Managing Director | Scout Energy Partners

We are excited to have John Baschab as a panelist for The Great Energy Debate session. He is a co-founder, manager of the General Partner and member of the investment committee at Scout. He is responsible for capital raising, investor relations, information technology, commodity product marketing and commodity product hedging.

John Baschab

John Baschab is co-founder, manager of the General Partner and member of the investment committee at Scout.  Scout is a private energy investment manager established in 2011 in Dallas Texas.  The Scout strategy focuses on acquiring and operating mature producing assets in the contiguous United States.  Scout has completed over 60 acquisitions and operates in five states producing over 120,000 gross boepd.  The firm currently has over $3.5 billion in assets under management across five funds and co-investment vehicles for 48 institutional partners.

John earned a BS from the University of Alabama and MBA from the University of Chicago Booth School of Business.  He was an adjunct professor at Southern Methodist University from 2003 to 2010 and is co-author of four books published by John Wiley & Sons, including OutperformInside the Investment Strategy of Billion Dollar Endowments (2010).

Libby Cantrill, CFA
Managing Director and Head of Public Policy | PIMCO

Libby is this year's opening keynote speaker. Ms. Cantrill analyzes policy and political risk for PIMCO’s Investment Committee and leads policymaker engagement and policy strategy for the firm. Prior to joining PIMCO, she served as a legislative aide in the House of Representatives. Libby is a regular contributor to Bloomberg and CNBC. She is a member of the Council on Foreign Relations and sits on the board of Covenant House New York.

Libby Cantrill, CFA

Ms. Cantrill is a managing director in PIMCO’s portfolio management group.  In her role, she analyzes policy and political risk for the firm’s Investment Committee and is a permanent member of the firm’s Americas Portfolio Committee, the committee that is responsible for the macroeconomic outlook for North America.  She also leads policymaker engagement and policy strategy for the firm and works closely with PIMCO’s Global Advisory Board, led by former Federal Reserve Chairman Ben Bernanke. She is a rotating member of the firm’s Executive Committee and a founding member of PIMCO Families and PIMCO Women. Prior to joining PIMCO in 2007, she served as a legislative aide in the House of Representatives and also worked in the investment banking division at Morgan Stanley. She has 17 years of investment experience and holds an MBA from Harvard Business School and received her undergraduate degree in economics from Brown University. Ms. Cantrill is a CFA charterholder and a regular contributor to Bloomberg and CNBC. She is also a member of the Council on Foreign Relations and sits on the board of Covenant House New York.

Eli Casdin
CIO and Founder | Casdin Capital

Eli will be a panelist on the Biotech panel. Mr. Casdin founded Casdin Capital in 2011 after nearly ten years spent focused on disruptive technologies and business models in life sciences and healthcare, including authoring the black book, The Dawn of Molecular Medicine. He also serves as a director or an observer on various boards for a number of public and private life sciences companies, trade groups and academic institutes.

Eli Casdin

Eli Casdin founded Casdin Capital in 2011 and serves as Chief Investment Officer and Founder. Casdin Capital engages as productive investor-partners, helping to fuel the visions of industry leaders by adding expertise and experience to their funding. Focused on emergent technologies in Life Sciences for more than two decades, Mr. Casdin has been active in both private and public capital markets, following a passion for analyzing and investing in new technologies and business models within the Life Sciences and healthcare industry.

Prior to founding Casdin Capital, Mr. Casdin served as vice president at Alliance Bernstein’s thematic investment arm, focusing personally on new technologies for the life sciences and healthcare sectors. While there he authored the 2011 black book, “The Dawn of Molecular Medicine,” detailing the (then) early-yet-accelerating wave of innovations transforming healthcare and creating opportunity for investors from testing to targeted medicine, diagnostics to industrial agriculture.

Earlier, he worked as a financial analyst at Bear Stearns and Cooper Hill Partners, a healthcare-focused investment firm.

Mr. Casdin earned a B.S. from Columbia University and an MBA from Columbia Business School. Today, he serves as a director or an observer on various boards for a number of public and private life sciences companies, trade groups and academic institutes including Rockefeller University, the New York Genome Center Board and The Columbia University School of General Studies Board of Visitors.

Ben Lamm
Co-Founder and CEO | Colossal

Ben will be joining Dr. Aldridge in the fireside chat on Bio Innovation through a New Lens. For over a decade, Ben has built disruptive businesses that future-proof our world, including Hypergiant, Conversable, and Chaotic Moon. Ben has appeared as a thought leader in many publications, including the Wall Street Journal, New York Times, Forbes, Entrepreneur, Wired, TechCrunch, VentureBeat, and Newsweek on topics such as innovation, technology and entrepreneurship. 

Ben Lamm

Ben Lamm is the co-founder and CEO of Colossal. Ben is a serial technology entrepreneur driven to solve the most complex challenges facing our planet. For over a decade, Ben has built disruptive businesses that future-proof our world. In addition to leading and growing his own companies, he is passionate about emerging technology, science, space and climate change. Active in angel investing, incubators and startup communities, Ben invests in software and emerging tech, and is deeply engaged in the technology, defense and climate change communities.

 

Prior to Colossal, Ben served as the founder and CEO to a number of companies, including Hypergiant, an enterprise AI software company focused on critical infractures, space, and defense;  Conversable,  the leading conversational intelligence platform that helps brands reach customers through automated experiences acquired by LivePerson; and Chaotic Moon, a global creative technology powerhouse acquired by Accenture. Ben was also the co-founder of Team Chaos, a consumer gaming company acquired by Zynga. 

 

Ben is a fellow of the Explorer's Club, whose mission is to promote the scientific exploration of land, sea, air, and space by supporting research and education in the physical, natural and biological sciences. He also serves as a Scientific Advisory Board member on the Planetary Society and sits on the Advisory Board for the Arch Mission.  Ben has appeared as a thought leader in many publications, including the Wall Street Journal, New York Times, Forbes, Entrepreneur, Wired, TechCrunch, VentureBeat, and Newsweek on topics such as innovation, technology and entrepreneurship. 

Tom Luce
CEO | Biotech Initiatives of Lyda Hill Philanthropies

Tom will be introducing the Pegasus Park Campus. Tom serves as CEO of Biotech Initiatives of Lyda Hill Philanthropies, which is focused on developing the entire life science ecosystem across the state of Texas. Tom has founded and lead numerous nonprofit organizations dedicated to serving the needs of others. Tom has authored two books on improving public education and has taught at several prestigious universities.

Tom Luce

Tom Luce’s life has been one of family, professional accomplishments, public service, and social entrepreneurship.

He received his undergraduate and law degrees from Southern Methodist University where he has been honored as a Distinguished Alumni. Tom went on to become the founding and managing partner of the Hughes and Luce law firm. He was lead attorney on multibillion mergers and litigation and was selected at various points in his career as one of the best attorneys at local, state, and national levels.

His public service in Texas was distinguished by gubernatorial and legislative appointments to major state positions including Chief Justice of the Supreme Court pro tempore, Sunset Commission, Cancer Prevention and Research Institute, Texas Commission on Judiciary, Chief of Staff of the Select Committee on Public Education, and the Superconducting Super Collider.

On the national level, he was appointed as Assistant Secretary of Education by President George W. Bush, confirmed by the United States Senate, and appointed to The Library of Congress Board by the Speaker of the U.S. House of Representatives.

Tom went on to found Texas 2036, an organization dedicated to addressing the impact of the state’s growth by an estimated 10 million people when it turns 200 years old. In addition to Texas 2036, Tom has founded and lead numerous other nonprofit organizations dedicated to serving the needs of others. These include the Texas Business and Education Coalition, Just for the Kids, Data Quality Campaign, the National Center for Educational Accountability, the National Math and Science Initiative, and the Meadows Mental Health Policy Institute.

His latest venture is serving as CEO of Biotech Initiatives of Lyda Hill Philanthropies, focused on developing the entire life science ecosystem across the state of Texas.

He has authored two books on improving public education and has taught at the Kennedy School of Government at Harvard, the University of Texas LBJ School of Public Affairs, Southern Methodist University, and the University of Texas at Dallas.

Tom has been married to his wife, Pam, for more than 60 years. They have three children and seven grandsons.

Kush Parmar, M.D., Ph.D.
Managing Partner | 5AM Ventures

Kush will be a panelist on the Biotech panel. He is a Managing Partner at 5AM Ventures. Dr. Parmar serves as a Director on the Boards of Akouos, Entrada, Homology (NASDAQ: FIXX), Rally Bio and Vor Biopharma. Dr. Parmar also serves on the Advisory Boards of Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation.

Kush Parmar, M.D., Ph.D.

Kush M. Parmar, M.D., Ph.D. is a Managing Partner at 5AM Ventures. Dr. Parmar serves as a Director on the Boards of Akouos, Entrada, Homology (NASDAQ: FIXX), Rally Bio and Vor Biopharma. He previously served as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J) and served as Board Member or Observer for Achaogen (NASDAQ: AKAO), Arvinas (NASDAQ: ARVN), Audentes (NASDAQ: BOLD), Envoy (acquired by Takeda) and scPharmaceuticals (NASDAQ: SCPH). Dr. Parmar serves on the Advisory Boards of Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Prior to 5AM, Dr. Parmar was at Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. At Princeton University, Dr. Parmar worked on developmental genetics with Eric F. Wieschaus (Nobel Prize in Medicine in 1995). He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School. Dr. Parmar is based in the Boston, MA office.

Rod Saddington, CFA
CEO, CIO, and Founder | Merewether Investment Management

Rod will be a panelist on the Great Energy Debate panel. Mr. Saddington is CEO, CIO, and founder of Merewether Investment Management (MIM), a $1.1BN AUM asset manager focused on long-short investing in equities across the entire energy value chain. Prior to founding MIM, Mr. Saddington was a Portfolio Manager for Carlson Capital, Managing Director for Och-Ziff Capital, and he began his work in the energy sector at Morgan Stanley.

Rod Saddington, CFA

Mr. Saddington is CEO, CIO, and founder of Merewether Investment Management (MIM). MIM is a $1.1BN AUM asset manager focused on long-short investing in equities across the entire energy value chain including traditional energy and new energy sectors. MIM has 2 products currently available to investors, the MIM Cyclicals Fund and the MIM Clean Energy Fund. Prior to founding MIM, Mr. Saddington was a Portfolio Manager at Carlson Capital and managed multiple strategies in excess of $1 billion in investments. Before his time there, he was a Managing Director at Och-Ziff Capital where he was responsible for U.S. public market energy investments and for sourcing, executing and managing private market energy investments. Mr. Saddington began his work in the energy sector at Morgan Stanley, where he was an investment banker in the power and energy sectors and an investment analyst on the Morgan Stanley Proprietary Trading desk as part of a two-person team running a global energy investment strategy. Mr. Saddington holds a B.S. in Commerce with majors in accounting and finance from the University of Sydney. He was also awarded First Class Honors in finance from the University of Sydney (U.S. Masters equivalent). He has been a CFA charter holder since 2004.

VENUE

Pegasus Park Campus

2020 04 20 Pegasus View_Final - reducedfile size

Address: 3000 Pegasus Park Drive, Dallas, TX 75247

Pegasus Park is a 23-acre future focused campus offering state-of-the-art facilities and amenities for the daily convergence of entrepreneurs, best of breed companies, strategic business partners, social impact organizations, and Dallas’ emerging biotech ecosystem. 

INTERESTED IN OTHER EVENTS?
CHECK OUT OUR SCHEDULE!

VIEW UPCOMING EVENTS